Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomark Diagnostics Inc (BUX.CN)

Biomark Diagnostics Inc (BUX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 58,851
  • Shares Outstanding, K 105,090
  • Annual Sales, $ 154 K
  • Annual Income, $ -1,927 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.96
  • Price/Sales 436.85
  • Price/Cash Flow N/A
  • Price/Book 68.16

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4700 +17.02%
on 02/03/26
0.6000 -8.33%
on 02/24/26
+0.0500 (+10.00%)
since 01/26/26
3-Month
0.3600 +52.78%
on 11/28/25
0.6000 -8.33%
on 02/24/26
+0.1900 (+52.78%)
since 11/26/25
52-Week
0.2000 +175.00%
on 03/07/25
0.6000 -8.33%
on 02/24/26
+0.3200 (+139.13%)
since 02/26/25

Most Recent Stories

More News
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic CapabilitiesVancouver, British Columbia--(Newsfile Corp. - January...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark: 2025 Achievements & 2026 Vision

Celebrating A Year of Extraordinary AchievementVancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors

Expanding U.S. market access with an experienced technology investor and AI-driven growth strategistVancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX)...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE:...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala

Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening PlatformVancouver, British Columbia--(Newsfile Corp. - December 1,...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosisVancouver, British Columbia--(Newsfile...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
Upcoming Meeting Dates - October 20, 2025

Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

ENBI.CN : 0.1000 (unch)
RV.VN : 0.055 (unch)
SILV.VN : 0.290 (-6.45%)
FMM.VN : 0.065 (+30.00%)
ATHR.CN : 0.0250 (unch)
AJN.CN : 0.2300 (unch)
CTTT.CN : 0.4800 (+5.49%)
AUEN.VN : 0.330 (unch)
SVE.VN : 0.710 (+1.43%)
LA.VN : 14.500 (+2.47%)
BIRD.VN : 0.085 (-10.53%)
CMC.VN : 0.065 (-7.14%)
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.Vancouver,...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.Vancouver, British Columbia--(Newsfile Corp. -...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone MarketsVancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE:...

BUX.CN : 0.5500 (-1.79%)
BMKDF : 0.3774 (-6.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research...

See More

Key Turning Points

3rd Resistance Point 0.5933
2nd Resistance Point 0.5767
1st Resistance Point 0.5633
Last Price 0.5500
1st Support Level 0.5333
2nd Support Level 0.5167
3rd Support Level 0.5033

See More

52-Week High 0.6000
Last Price 0.5500
Fibonacci 61.8% 0.4472
Fibonacci 50% 0.4000
Fibonacci 38.2% 0.3528
52-Week Low 0.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar